[The pharmacological treatment of obesity: past, present and future].

Orv Hetil

Pest Megyei Flór Ferenc Kórház, Kardiometabolikus Centrum V. Belgyógyászat-Lipidológiai Osztály, Regionális Zsíranyagcsere-központ és Hypertonia Decentrum, Budapest.

Published: March 2012

AI Article Synopsis

  • Obesity is a major health issue, and effective management for weight loss includes lifestyle changes (like diet and exercise), behavioral therapy, pharmacological treatments, and sometimes surgery.
  • While diet and exercise are ideal, they require discipline and can be tough to stick with; drug treatments can assist but often have modest results and lead to weight regain once stopped.
  • Currently, orlistat is the only long-term anti-obesity drug approved, while new options like liraglutide are being researched for their potential in weight management.*

Article Abstract

Currently, obesity presents one of the biggest health problems. Management strategies for weight reduction in obese individuals include changes in life style such as exercise and diet, behavioral therapy, and pharmacological treatment, and in certain cases surgical intervention. Diet and exercise are best for both prevention and treatment, but both require much discipline and are difficult to maintain. Drug treatment of obesity offer a possible adjunct, but it may only have modest results, limited by side effects; furthermore, the weight lowering effects last only as long as the drug is being taken and, unfortunately, as soon as the administration is stopped, the weight is regained. These strategies should be used in a combination for higher efficacy. Drugs used to induce weight loss have various effects: they increase satiety, reduce the absorption of nutrients or make metabolism faster; but their effect is usually moderate. In the past, several drugs were used in the pharmacological therapy of weight reduction including thyroid hormone, dinitrophenol, amphetamines and their analogues, e.g. fenfluramine, At present, only orlistat is available in the long term treatment (≥ 24 weeks) of obesity as sibutramine and rimonabant were withdrawn form the market. Several new anti-obesity drugs are being tested at present, and liraglutide, a GLP-1 analogue (incretin mimetic), is the most promising one.

Download full-text PDF

Source
http://dx.doi.org/10.1556/OH.2012.29317DOI Listing

Publication Analysis

Top Keywords

pharmacological treatment
8
treatment obesity
8
weight reduction
8
treatment
5
weight
5
[the pharmacological
4
obesity
4
obesity future]
4
future] currently
4
currently obesity
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!